Filing Flows

Filing Flows › Collegium Pharmaceutical (COLL) › Next earnings date

Collegium Pharmaceutical (COLL) earnings: beat the estimate

Collegium Pharmaceutical (COLL) reported on Nov 5, 2026 and beat the EPS estimate: $1.96 against $1.86 (+5.6%). Revenue was $216M for Q3 2026, +3% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+5.6% vs estimate
Beat rate80%

The last report

Collegium Pharmaceutical reported revenue of $216M for the third quarter 2026 (+3% Y/Y), net earnings $21.8M: Belbuca $57.7M, Jornay PM $51.9M, Xtampza ER $45.8M, Azstarys $26.5M. How it makes money → · Every quarter →

Collegium Pharmaceutical: EPS against the estimate, last 5 reportsCollegium Pharmaceutical: EPS against the estimate, last 5 reportsEstimateReported$1.86$2.25Nov 25$2.14$2.04Feb 26$1.52$1.76May 26$1.76$1.92Aug 26$1.86$1.96Nov 26
Latest (Nov 26): Estimate $1.86, Reported $1.96.
COLL: the stock's move on each reportCOLL: the stock's move on each reportAug 6, 2026-17.5%May 7, 2026+3.5%Feb 26, 2026-8.9%Nov 6, 2025+18.0%

Collegium Pharmaceutical's latest quarter

Collegium Pharmaceutical, Q3 2026: revenue $216M (+3% year over year), operating margin 13.3%, net earnings $21.8M, operating cash flow $86.5M. The chart follows the revenue to costs, profit and cash.

Questions

Did Collegium Pharmaceutical beat earnings?

Collegium Pharmaceutical (COLL) reported on Nov 5, 2026 and beat the EPS estimate: $1.96 against $1.86 (+5.6%).

When does COLL report earnings?

The next date is not set yet.

Does Collegium Pharmaceutical usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.